1. Chemotherapy: a double-edged sword in cancer treatment

   • Nafiseh Behranvand
   • Farzad Nasri
   • Reza Falak

   Review 05 August 2021 Pages: 507 - 526

   

2. Correction to: Chemotherapy: a double‑edged sword in cancer treatment

   • Nafiseh Behranvand
   • Farzad Nasri
   • Reza Falak

   Correction 28 August 2021 Pages: 527 - 527

3. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma

   • Anneloes van Duijn
   • Karin J. Willemsen
   • Walbert J. Bakker

   Original Article Open access 15 July 2021 Pages: 529 - 540

   

4. Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer

   • Elgin Hoffmann
   • Frank Paulsen
   • Franziska Eckert

   Original Article Open access 16 July 2021 Pages: 541 - 552

   

5. Transcriptomic signatures of tumors undergoing T cell attack

   • Aishwarya Gokuldass
   • Aimilia Schina
   • Marco Donia

   Original Article 17 July 2021 Pages: 553 - 563

   

6. Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma

   • Tomoya Mizuno
   • Takao Kamai
   • Ken-Ichiro Yoshida

   Original Article Open access 18 July 2021 Pages: 565 - 578

   

7. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors

   • Da Hyun Kang
   • Chaeuk Chung
   • Jeong Eun Lee

   Original Article Open access 18 July 2021 Pages: 579 - 588

   

8. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma

   • Masahiro Ohira
   • Ryuichi Hotta
   • Hideki Ohdan

   Original Article 19 July 2021 Pages: 589 - 599

   

9. Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq

   • Hongkai Zhuang
   • Xinming Chen
   • Baohua Hou

   Original Article 19 July 2021 Pages: 601 - 612

   

10. Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21

    • Jaya Lakshmi Thangaraj
    • Minh-Trang Thi Phan
    • Je-Jung Lee

    Original Article 20 July 2021 Pages: 613 - 625

    

11. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody

    • Tamara Mateu-Albero
    • Raquel Juárez-Sánchez
    • Carlos Cuesta-Mateos

    Original Article 23 July 2021 Pages: 627 - 636

    

12. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

    • Hui Yu
    • Ping Chen
    • Bei Zhang

    Original Article 23 July 2021 Pages: 637 - 644

    

13. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas

    • Houshi Xu
    • Anke Zhang
    • Meiqing Lou

    Original Article 27 July 2021 Pages: 645 - 660

    

14. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection

    • Xiuxing Chen
    • Ziming Du
    • Yuhong Li

    Original Article 28 July 2021 Pages: 661 - 674

    

15. A comprehensive model based on temporal dynamics of peripheral T cell repertoire for predicting post-treatment distant metastasis of nasopharyngeal carcinoma

    • Yajing Zhang
    • Yujie Zhu
    • Ye Zhang

    Original Article 03 August 2021 Pages: 675 - 688

    

16. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia

    • Xian Zhang
    • Junfang Yang
    • Peihua Lu

    Original Article 07 August 2021 Pages: 689 - 703

    

17. The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells

    • Pin-Jui Kung
    • Ting-Yu Lai
    • Chih-Yuan Lee

    Original Article Open access 10 August 2021 Pages: 705 - 718

    

18. Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials

    • Thierry Landre
    • Gregoire Justeau
    • Boris Duchemann

    Original Article 10 August 2021 Pages: 719 - 726

    

19. Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer

    • Mizuki Kobayashi
    • Nobuhiro Fujiyama
    • Masaki Shiota

    Original Article 11 August 2021 Pages: 727 - 736

    

20. Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

    • Hiroshi Takumida
    • Hidehito Horinouchi
    • Yuichiro Ohe

    Original Article Open access 14 August 2021 Pages: 737 - 746

    

21. An immune-related prognostic signature for thyroid carcinoma to predict survival and response to immune checkpoint inhibitors

    • Pu Wu
    • Wei Sun
    • Hao Zhang

    Original Article 16 August 2021 Pages: 747 - 759